^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + vidutolimod (CMP-001) (Immunomodulator, TLR9 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Checkmate Pharmaceuticals Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade in the Treatment of Certain Types of Metastatic or Unresectable Melanoma
Published date:
07/27/2020
Excerpt:
...the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its product candidate, CMP-001, a differentiated Toll-like receptor 9 (TLR9) agonist, in combination with a programmed death receptor 1 (PD-1) blocking antibody (nivolumab or pembrolizumab) for two development programs, including:...initial treatment of patients with unresectable Stage III or Stage IV melanoma to prolong the time to disease progression; and...treatment of patients with unresectable or metastatic melanoma refractory to prior anti-PD-1 blockade to improve the overall tumor response rate.
